NCT00504907

Safety Study of Oral BTA9881 to Treat RSV Infection

A Phase I, Single-Centre, Double-Blind, Placebo-Controlled, Escalating Single Oral Dose, Safety and Tolerability Clinical Trial With BTA9881 in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 63 (actual)
• Sponsor: Biota Scientific Management Pty Ltd · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

This is a placebo-controlled, double-blind, randomised, single dose escalation Phase I clinical trial to determine the safety and tolerability of BTA9881 administered orally to healthy subjects

Conditions

• Respiratory Syncytial Virus Infections

Interventions

Type	Name	Description
DRUG	BTA9881	Single oral escalating doses
DRUG	Placebo

Timeline

• Start date: 2007-07-01
• Primary completion: 2008-12-01
• Completion: 2008-12-01
• First posted: 2007-07-20
• Last updated: 2018-05-30

Locations

1 site across 1 country: Australia